| Literature DB >> 33806001 |
Uros Glavinic1, Jevrosima Stevanovic1, Marko Ristanic1, Milan Rajkovic1, Dajana Davitkov2, Nada Lakic3, Zoran Stanimirovic1.
Abstract
Depending on the infection level and colony strength, Nosema ceranae, a microsporidian endoparasite of the honey bee may have significant consequences on the health, reproduction and productivity of bee colonies. Despite exerting some side effects, fumagillin is most often used for Nosema control. In this study, in a cage experiment, N. ceranae infected bees were treated with fumagillin or the extract of Agaricus blazei mushroom, a possible alternative for Nosema control. Bee survival, Nosema spore loads, the expression levels of immune-related genes and parameters of oxidative stress were observed. Fumagillin treatment showed a negative effect on monitored parameters when applied preventively to non-infected bees, while a noticeable anti-Nosema effect and protection from Nosema-induced immunosuppression and oxidative stress were proven in Nosema-infected bees. However, a protective effect of the natural A. blazei extract was detected, without any side effects but with immunostimulatory activity in the preventive application. The results of this research suggest the potential of A. blazei extract for Nosema control, which needs to be further investigated.Entities:
Keywords: Agaricus blazei; Nosema ceranae; antioxidative protection; fumagillin; honey bee; immune-related gene expression; immunostimulation; mushroom extract
Year: 2021 PMID: 33806001 PMCID: PMC8064457 DOI: 10.3390/insects12040282
Source DB: PubMed Journal: Insects ISSN: 2075-4450 Impact factor: 2.769
Figure 1Frames with sealed brood placed in net bags [27].
Experimental design.
| GROUP 1 | Beginning of Treatment 2 | Sampling Day 2 | ||||
|---|---|---|---|---|---|---|
| Controls | NI | - | - | 6 | 9 | 15 |
| I | - | 3 | 6 | 9 | 15 | |
| Fumagillin-treated bees | F | 1 | - | 6 | 9 | 15 |
| I-F1 | 1 | 3 | 6 | 9 | 15 | |
| I-F3 | 3 | 3 | 6 | 9 | 15 | |
| I-F6 | 6 | 3 | - | 9 | 15 | |
| AB | 1 | - | 6 | 9 | 15 | |
| I-AB1 | 1 | 3 | 6 | 9 | 15 | |
| I-AB3 | 3 | 3 | 6 | 9 | 15 | |
| I-AB6 | 6 | 3 | - | 9 | 15 | |
1 Bees were non-infected (NI) or infected with N. ceranae (I) and treated with fumagillin (F) or A. blazei extract (AB). 2 Days after bee emergence.
Primer pairs used for qPCR analyses.
| Primer | Sequence 5’–3’ | Annealing Temperature, °C | Reference |
|---|---|---|---|
| Abaecin-F | CAGCATTCGCATACGTACCA | 60 | [ |
| Abaecin-R | GACCAGGAAACGTTGGAAAC | ||
| Beta actin-F | TTGTATGCCAACACTGTCCTTT | 60 | [ |
| Beta actin-R | TGGCGCGATGATCTTAATTT | ||
| ApidNT-F | TTTTGCCTTAGCAATTCTTGTTG | 60 | [ |
| ApidNT-R | GTAGGTCGAGTAGGCGGATCT | ||
| Defensin-F | TGCGCTGCTAACTGTCTCAG | 60 | [ |
| Defensin-R | AATGGCACTTAACCGAAACG | ||
| Hymenopt-F | CTCTTCTGTGCCGTTGCATA | 60 | [ |
| Hymenopt-R | GCGTCTCCTGTCATTCCATT | ||
| VgMC-F | AGTTCCGACCGACGACGA | 60 | [ |
| VgMC-R | TTCCCTCCCACGGAGTCC |
Figure 2Effects of treatment with fumagillin and A. blazei extract on the survival rate of N. ceranae infected bees. Survival rate was based on the daily accumulated mortality. The comparison was made between the non-infected control (NI), N. ceranae infected control (I) and groups infected and treated with fumagillin from day 1 (I-F1), day 3 (I-F3) and day 6 (I-F6) or A. blazei extract from day 1 (I-AB1), day 3 (I-AB3) and day 6 (I-AB6). Group names are indicated in Table 1.
Figure 3Nosema spore loads in infected control (I) and groups infected and treated with fumagillin from day 1 (I-F1), day 3 (I-F3) and day 6 (I-F6) or A. blazei extract from day 1 (I-AB1), day 3 (I-AB3) and day 6 (I-AB6). Group names are indicated in Table 1. Groups labelled with the same letter did not differ significantly. The same font size (lowercase or uppercase) refers to the same time point.
Figure 4Heatmaps: (A) mean values for superoxide dismutase (SOD), catalase (CAT) and glutathione S-transferase (GST) activities and malondialdehyde (MDA) concentration; (B) immune-related genes (medians of Log2 of relative expression ratios for abaecin, hymenoptaecin, defensin, apidaecin and vitellogenin) at different time points in experimental groups. Non-infected control (NI), N. ceranae infected control (I) and groups infected and treated with fumagillin from day 1 (I-F1), day 3 (I-F3) and day 6 (I-F6) or A. blazei extract from day 1 (I-AB1), day 3 (I-AB3) and day 6 (I-AB6). Group names are indicated in Table 1.